Glenmark Pharmaceuticals ltd — Capital/Financing Update 2025

Sep 24, 2025

==> picture [33 x 32] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

September 24, 2025

To, To,

Dy. General Manager The Manager – Listing,

Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd. Plot No. C/1, G Block

Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296 Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions

With reference to the subject mentioned above, kindly find attached media release which is selfexplanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK VINAYAK KUBER Date: 2025.09.24 KUBER 15:30:04 +05'30'

Harish Kuber Company Secretary & Compliance Officer

Encl: As above

Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [601 x 133] intentionally omitted <==

Glenmark Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions

Partnership reinforces Glenmark’s innovation-led strategy and commitment to expanding access to breakthrough cancer therapies

Mumbai, September 24, 2025 : Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), today announced that it has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC).

Under the terms of the agreement, Glenmark obtains exclusive rights to develop and commercialize Trastuzumab Rezetecan (SHR-A1811) worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, Taiwan Region, USA, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan. Glenmark will pay an upfront payment of US$18 million. Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion. Based on the net sales of Trastuzumab Rezetecan within the licensed territory, Glenmark will pay corresponding royalties to Hengrui.

“We are delighted to collaborate with Hengrui and build on the scientific momentum of SHR-A1811 as we continue expanding our oncology pipeline and leadership. This partnership aligns strongly with our strategy to bring differentiated, high-value therapies to patients and reinforces our commitment to advancing innovation in areas of significant unmet need,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Limited.

“Facing the major global challenge of cancer treatment, Hengrui has over the years accelerated the research and development of cutting-edge innovative therapies such as ADCs and is committed to addressing clinical treatment challenges and meeting unmet medical needs. This collaboration with Glenmark is a significant step in Hengrui’s ongoing strategy to deepen its presence in emerging markets. We look forward to working together to enhance the accessibility of innovative therapies and to bring new hope to patients in more countries and regions,” said Jo Feng, President of Hengrui Pharma.

Trastuzumab Rezetecan is Hengrui’s self-developed HER2-targeted ADC. In May 2025, it was approved in China for the treatment of adult patients with HER2 (ERBB2) activating mutations in unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. This is the first China-developed ADC approved for HER2-mutated NSCLC. In September 2025, the new indication for

==> picture [612 x 36] intentionally omitted <==

==> picture [601 x 133] intentionally omitted <==

Trastuzumab Rezetecan in breast cancer was accepted by China’s NMPA for review and was included in the priority review program. To date, Trastuzumab Rezetecan has been included in the NMPA’s Breakthrough Therapy Designation list for nine indications, covering NSCLC, breast cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal cancer, biliary tract cancer, and gynecologic malignancies.

Currently, Trastuzumab Rezetecan is actively advancing multiple clinical trials. In August 2025, Trastuzumab Rezetecan in combination with adebrelimab and chemotherapy obtained Orphan Drug Designation from the US FDA for gastric or gastroesophageal junction adenocarcinoma.

This collaboration marks a significant step forward in Glenmark’s focused oncology strategy, particularly in complex biologics. It reinforces Glenmark’s long-term commitment to delivering next-generation therapies across high-burden, underserved geographies.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 4.5 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (Glenmark_pharma).

About Hengrui Pharma

Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.

For more information, please contact:

Aakanksha Pilay

==> picture [612 x 36] intentionally omitted <==

==> picture [601 x 133] intentionally omitted <==

aakanksha.pilay@glenmarkpharma.com Glenmark Pharmaceuticals

Hengrui Pharmaceuticals DGA Group hengrui@dgagroup.com

==> picture [612 x 36] intentionally omitted <==